Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats

I. Vaněčková, P. Kujal, Z. Husková, Z. Vaňourková, Z. Vernerová, V. Certíková Chábová, P. Skaroupková, HJ. Kramer, V. Tesař, L. Červenka

. 2012 ; 35 (5) : 382-392.

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc13000886

Grant support
NS10500 MZ0 CEP Register
NS9703 MZ0 CEP Register
NT12171 MZ0 CEP Register

Our previous studies in rats with ablation nephrectomy have shown similar cardiorenal protective effects of renin-angiotensin system (RAS)-dependent treatment (combination of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker) and RAS-independent treatment (combination of α- and β-adrenoreceptor antagonist and diuretics). Moreover, selective blockade of endothelin (ET) receptor type A (ET(A)) improved survival rate and attenuated hypertension and organ damage in Ren-2 transgenic rats. Therefore, we were interested in whether ET(A) receptor blockade could have additive effects to the classical blockade of the RAS. Transgenic rats underwent 5/6 renal ablation at the age of 2 months and were treated for 20 weeks with RAS blockers alone (angiotensin II receptor blocker - losartan, and angiotensin-converting enzyme inhibitor - trandolapril), ET(A) receptor blocker alone (atrasentan) or with the combination of RAS and ET(A) receptor blockade. RAS blockade normalized blood pressure and improved survival. It decreased cardiac hypertrophy and proteinuria as well as tissue angiotensin II and ET-1 levels. In contrast, ET(A) receptor blockade only partially improved survival rate, reduced blood pressure, attenuated the development of cardiac hypertrophy and transiently reduced proteinuria. However, no additive cardio- and renoprotective effects of ET(A) and RAS blockade were noted at the end of the study.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13000886
003      
CZ-PrNML
005      
20191024111742.0
007      
ta
008      
130108s2012 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000336823 $2 doi
035    __
$a (PubMed)22487948
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Vaněčková, Ivana, $u Institute of Physiology v.v.i., Academy of Sciences of the Czech Republic, Prague, Czech Republic; Cardiovascular Research Center, Prague, Czech Republic. ivanava@biomed.cas.cz $d 1964- $7 xx0030586
245    10
$a Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats / $c I. Vaněčková, P. Kujal, Z. Husková, Z. Vaňourková, Z. Vernerová, V. Certíková Chábová, P. Skaroupková, HJ. Kramer, V. Tesař, L. Červenka
520    9_
$a Our previous studies in rats with ablation nephrectomy have shown similar cardiorenal protective effects of renin-angiotensin system (RAS)-dependent treatment (combination of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker) and RAS-independent treatment (combination of α- and β-adrenoreceptor antagonist and diuretics). Moreover, selective blockade of endothelin (ET) receptor type A (ET(A)) improved survival rate and attenuated hypertension and organ damage in Ren-2 transgenic rats. Therefore, we were interested in whether ET(A) receptor blockade could have additive effects to the classical blockade of the RAS. Transgenic rats underwent 5/6 renal ablation at the age of 2 months and were treated for 20 weeks with RAS blockers alone (angiotensin II receptor blocker - losartan, and angiotensin-converting enzyme inhibitor - trandolapril), ET(A) receptor blocker alone (atrasentan) or with the combination of RAS and ET(A) receptor blockade. RAS blockade normalized blood pressure and improved survival. It decreased cardiac hypertrophy and proteinuria as well as tissue angiotensin II and ET-1 levels. In contrast, ET(A) receptor blockade only partially improved survival rate, reduced blood pressure, attenuated the development of cardiac hypertrophy and transiently reduced proteinuria. However, no additive cardio- and renoprotective effects of ET(A) and RAS blockade were noted at the end of the study.
650    _2
$a blokátory receptorů AT1 pro angiotensin II $x farmakologie $7 D047228
650    _2
$a inhibitory ACE $x farmakologie $7 D000806
650    _2
$a zvířata $7 D000818
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a renální hypertenze $x farmakoterapie $x mortalita $x patologie $7 D006977
650    _2
$a indoly $x farmakologie $7 D007211
650    _2
$a ledviny $x patologie $7 D007668
650    _2
$a losartan $x farmakologie $7 D019808
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nefrektomie $x metody $7 D009392
650    _2
$a pyrrolidiny $x farmakologie $7 D011759
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a potkani transgenní $7 D055647
650    _2
$a receptor angiotensinu typ 1 $x metabolismus $7 D044140
650    _2
$a receptor endotelinu A $x metabolismus $7 D044022
650    _2
$a chronická renální insuficience $x farmakoterapie $x mortalita $x patologie $7 D051436
650    _2
$a renin-angiotensin systém $x účinky léků $x fyziologie $7 D012084
650    _2
$a analýza přežití $7 D016019
650    _2
$a výsledek terapie $7 D016896
650    _2
$a antagonisté endotelinového receptoru A $7 D065130
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kujal, Petr $u Department of Pathology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic; Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $7 xx0244311
700    1_
$a Husková, Zuzana, $u Cardiovascular Research Center, Prague, Czech Republic; Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $d 1978- $7 xx0074206
700    1_
$a Vaňourková, Zdeňka, $u Cardiovascular Research Center, Prague, Czech Republic; Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $d 1973- $7 xx0074217
700    1_
$a Vernerová, Zdenka, $u Department of Pathology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic $d 1960-2020 $7 jo2002104672
700    1_
$a Čertíková-Chábová, Věra $u Cardiovascular Research Center, Prague, Czech Republic; Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $7 xx0095872
700    1_
$a Škaroupková, Petra $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $7 xx0117683
700    1_
$a Kramer, Herbert J. $u Section of Nephrology, Medical Policlinic, Department of Medicine, University of Bonn, Bonn, Germany
700    1_
$a Tesař, Vladimír $u Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Červenka, Luděk, $u Cardiovascular Research Center, Prague, Czech Republic; Department of Physiology, 2nd Medical Faculty, Charles University, Prague, Czech Republic; Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $d 1967- $7 xx0037105
773    0_
$w MED00003064 $t Kidney & blood pressure research $x 1423-0143 $g Roč. 35, č. 5 (2012), s. 382-392
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22487948 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130108 $b ABA008
991    __
$a 20191024112217 $b ABA008
999    __
$a ok $b bmc $g 963668 $s 799050
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 35 $c 5 $d 382-392 $i 1423-0143 $m Kidney & blood pressure research $n Kidney Blood Press Res $x MED00003064
GRA    __
$a NS10500 $p MZ0
GRA    __
$a NS9703 $p MZ0
GRA    __
$a NT12171 $p MZ0
LZP    __
$a Pubmed-20130108

Find record

Citation metrics

Archiving options